[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550306":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":27,"responsibleParty":43,"collaborators":19,"id":45,"slug":19,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":19,"enrollmentInfo":54,"targetDuration":19,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Ziekenhuis Oost-Limburg","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Study cohort","FibroScan measurement",[12],"Diagnostic Test: FibroScan",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","FibroScan","Performance of a FibroScan measurement to determine steatosis and fibrosis.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Leen Heyens, MsC","CONTACT","089 21 20 55","+32","nafldstudie@zol.be",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Genk","Limburg","3600","Belgium",{"type":35,"coordinates":36},"Point",[37,38],5.50082,50.965,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":42},"NAFLDstudie@zol.be",{"type":44,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100550306",false,"NCT06445361","Prevalence of NAFLD in T1DM Patients","The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium","PAD1ZOL","Inclusion Criteria:\n\n* T1DM\n* ≥ 18 years of age\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Excessive alcohol use\n* Exclusion of other causes of liver disease and secondary causes of liver steatosis","ALL","18 Years",{"count":55,"type":56},138,"ESTIMATED","INTERVENTIONAL",[59],"NA","To determine the prevalence of NAFLD in T1DM patients.",[62,63,64],"NAFLD","Type 1 Diabetes","Fatty Liver, Nonalcoholic","2025-07-22",{"date":67,"type":68},"2025-07-28","ACTUAL",{"date":70,"type":68},"2023-07-01",{"date":72,"type":56},"2026-07-01",{"name":5,"class":6},1]